Benitec Biopharma Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BNTC | SLDB | PRQR | DTIL | ABEO | DSGN | |
|---|---|---|---|---|---|---|
| Market cap | 323.77M | 699.11M | 198.98M | 226.84M | 241.32M | 665.24M |
| P/E (TTM) | — | — | — | 32.5 | — | — |
| Forward P/E | -1.0 | -3.8 | -3.0 | -4.4 | -20.3 | -6.6 |
| Price/book | 1.8 | 2.9 | 2.2 | 4.4 | 1.9 | 3.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −46.77% | +54.69% | −42.44% | +5.29% | +0.72% | +54.73% |
| Today | +10.48% | +3.82% | +2.92% | +16.50% | −0.71% | +2.80% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BNTC news ›Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
The BB-301 pivotal trial remains on track to begin in mid-2027 Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested ... Benitec Biopharma Announces…
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301
- Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic Patients with Oculopharyngeal Muscular Dystrophy (OPMD) - 100% of Patients treated with BB-301 across both doses are formal…
Benitec Biopharma announces interim results from BB-301 trial
Benitec Biopharma (BNTC) announced interim clinical results from the ongoing BB-301 Phase 1b/2a first-in-human study for Patients treated with h... Benitec Biopharma announces interim results from BB-301 trial Benitec Biopharma (BNTC)…
Benitec Biopharma Announces Virtual Annual Stockholder Meeting for December 3, 2026
Kalkine Media On October 20, 2026, Benitec Biopharma Inc. submitted Definitive Additional Materials via a Schedule 14A proxy notice, confirming its Annual Meeting of Stockholders set for December 3, 2026, at 1:00 p.m
Benitec Biopharma Inc. Stock 12‑Month Price Target Raised to $24.33, Implies 171% Upside
TradingView Benitec Biopharma Inc. Stock 12‑Month Price Target Raised to $24.33, Implies 171% Upside - According to estimates from 6 analysts, Benitec Biopharma Inc. stock's average price target has risen from
Analysts Are Bullish on These Healthcare Stocks: Repligen (RGEN), Benitec Biopharma (BNTC)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repligen (RGEN), Benitec Biopharma (BNTC) and Zymeworks (ZYME) with bullish sentiments. Stifel Nicolaus analyst Daniel Arias maintained a Buy…
Benitec Biopharma initiated with an Outperform at Raymond James
Raymond James analyst Tiago Fauth initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $14 price target Benitec is a cl... Benitec Biopharma initiated with an Outperform at Raymond James Raymond James analyst Tiago…
Benitec Biopharma says BB-301 pivotal still on track for mid-2027
Benitec announced formal FDA feedback following a Type C meeting in Q3. Discussions on an open-label, single-arm pivotal study for BB-301 are on... Benitec Biopharma says BB-301 pivotal still on track for mid-2027 Published first on TheFly…
Analysts Conflicted on These Healthcare Names: High Tide (HITI), Cardiff Oncology (CRDF) and Benitec Biopharma (BNTC)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on High Tide (HITI), Cardiff Oncology (CRDF) and Benitec Biopharma (BNTC). Roth MKM analyst Bill Kirk maintained a Buy rating on High Tide today and set a price…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com8
- tradingview.com2
- kalkinemedia.com1
- manilatimes.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.